Mediators of Inflammation
Volume 2019 (2019), Article ID 8419439, 2 pages
https://doi.org/10.1155/2019/8419439

Erratum

Erratum to “Increased Expression of TLR10 in B Cell Subsets Correlates with Disease Activity in Rheumatoid Arthritis”

Ying Zhang,1,2 Rong Cao,¹ Haijian Ying,² Juping Du,² Shuaishuai Chen,² Na Wang,² and Bo Shen¹

¹School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China
²Department of Clinical Laboratory, Taizhou Hospital of Zhejiang Province, Taizhou Enze Medical Center (Group), Taizhou, Zhejiang, China

Correspondence should be addressed to Bo Shen; shenbkz@aliyun.com

Received 23 January 2019; Accepted 27 January 2019; Published 10 March 2019

Copyright © 2019 Ying Zhang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Increased Expression of TLR10 in B Cell Subsets Correlates with Disease Activity in Rheumatoid Arthritis” [1], the email address of the corresponding author Bo Shen should be corrected as “shenbkz@aliyun.com.” In addition, the format of Table 1 was incorrect. This occurred due to a production error. The corrected Table is shown below.

Table 1: Clinical characteristics of the study subjects.

Healthy control group ()
All RA group ()
Low active RA group ()
Moderate active RA group ()
High active RA group ()

Female (%)
26 (86.7)
66 (85.7)
16 (84.2)
25 (86.2)
25 (86.2)

Age (years)

Disease duration (years)
—
5.0 (2-12)
3.5 (2-13)
7 (2.5-12.5)
4 (1.5-10)

RF (kU/l)a
—
65.1 (34.8-187)
63.1 (37.9-146.8)
62.1 (29.0-150)
93.5 (34.6-259)

RF-positive (%)a
—
62 (87.3)
15 (93.8)
24 (85.7)
23 (85.2)

Anti-CCP (U/ml)b
—
94.1 (31.7-532.3)
87.1 (22.4-536.1)
91.4 (49.2-501)
100.9 (34.8-574)

Anti-CCP-positive (%)b
—
67 (89.3)
16 (88.9)
26 (89.7)
25 (89.3)

CRP (mg/l)C
—
3.0 (0.9-9.9)
1.3 (0.8-3.6)
2.4 (0.9-9.3)
5.1 (1.2-17.3)

CRP positive (%)C
—
20 (28.6)
1 (6.7)
8 (27.6)
11 (42.3)

ESR (mm/h)
—
27 (18-42)
19 (11-26)
33 (23-46)
38 (21.5-51.5)

DAS28-ESR
—

Medicine use
—

    NSAIDs
—
16 (20.8)
2 (10.5)
8 (27.6)
6 (20.7)

    DMARDs
—
57 (74.0)
17 (89.5)
20 (69.0)
20 (69.0)

        Methotrexate
—
47 (61.0)
15 (78.9)
15 (51.7)
17 (58.6)

        Leflunomide
—
32 (41.6)
10 (52.6)
11 (37.9)
11 (37.9)

        Sulfasalazine
—
8 (10.4)
2 (10.5)
5 (17.2)
1 (3.4)

    Prednisolone
—
12 (15.6)
2 (10.5)
3 (10.3)
7 (24.1)

    Chinese medicine
—
16 (20.8)
4 (21.1)
7 (24.1)
7 (24.1)

    No treatment
—
7 (9.1)
1 (5.3)
2 (6.9)
4 (13.8)

    Otherd
—
4 (5.2)
1 (5.3)
2 (6.9)
1 (3.4)

    Unknowne
—
4 (5.2)
0 (0)
1 (3.4)
3 (10.3)

The data are expressed as (%), deviation (SD), or median (interquartile range, 25th-75th). DAS28-ESR: Disease Activity Score of 28 joints using ESR; NSAIDs: nonsteroidal anti-inflammatory drugs; DMARDs: disease-modifying antirheumatic drugs. aRF data were lacking in 6 subjects. Sixty-two out of 71 RA subjects were RF-positive. bAnti-CCP data were lacking in 2 subjects. Sixty-seven out of 75 RA subjects were anti-CCP-positive. cCRP data were lacking in 7 subjects. Twenty out of 70 RA subjects were CRP-positive. dThe patients defined as “other” included the following: those who were on their first visit to our hospital, were not on regular medication (one patient), and were taking other medicines that were not related to RA therapy (three patients). eThe patients defined as “unknown” included the following: those who were on their first visit to our hospital, could not tell which medication to use (two patients), and were only told of a few of their medicines (two patients).

References

Y. Zhang, R. Cao, H. Ying et al., “Increased expression of TLR10 in B cell subsets correlates with disease activity in rheumatoid arthritis,” Mediators of Inflammation, vol. 2018, Article ID 9372436, 10 pages, 2018.